PD-L1 blockade boosted by PARP inhibition: combination therapy for small cell lung cancer

Identifier:  TFG:5912

Handle: https://hdl.handle.net/20.500.11797/TFG5912

Authors:  Iñañez Blas, Albert

Abstract:
Small cell lung cancer (SCLC) is one of the most intractable diseases in the clinical practice. Very recently it has been added to the 1st line treatment the PD-L1 blockade together with cisplatin. However, response rates are very low. Combinatory therapies aim to boost the efficacy of anti-PD-L1 therapy. One of those combination therapies which has gain major interest is anti-PD-L1 and PARP inhibition. PARP proteins are an important family of proteins involved in the DNA damage repair. Although the clinical efficacy has been proven in other cancers, clinical trials have shown little benefits of the use of this therapeutic approach in SCLC.